Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam (Ruima) vs propofol for ICU sedation
CTR20220382Phase 3Completed
- Sponsor
- Yichang Humanwell Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of remimazolam in critical care sedation and mechanical ventilation (2 arms), sponsored by Yichang Humanwell Pharmaceutical Co., Ltd. Primary endpoints: PK/PD characteristics of remimazolam for ICU sedation, Percentage of time at target sedation level and 13 more. Started Feb 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
critical care sedationmechanical ventilation
Beyond the preview
Go deeper on CTR20220382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220382.